Table 6.
Incidence of CMV viremia and disease
.
G-CSF
.
IV plerixafor
.
Risk difference (95% CI)
.
CMV viremia ≥10 000 copies/mL
62% (43/69)
15% (3/20)
47% (23%, 69%)
CMV disease with preemptive treatment
6% (4/69)
5% (1/20)
0.8% (−24%, 25%)
.
G-CSF
.
IV plerixafor
.
Risk difference (95% CI)
.
CMV viremia ≥10 000 copies/mL
62% (43/69)
15% (3/20)
47% (23%, 69%)
CMV disease with preemptive treatment
6% (4/69)
5% (1/20)
0.8% (−24%, 25%)
View Large
Close Modal
Close Modal
This Feature Is Available To Subscribers Only
Sign In
or
Create an Account
Close Modal
Close Modal